Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy

Project description

Synergistic strategies for reversing vascular compression in cancer

In certain types of cancer, blood vessels endure compression due to stiffness caused by the intricate interactions between cancer cells and the tumour microenvironment. This leads to reduced blood flow, compromising drug delivery and effectiveness, as well as helping cancer cells evade immune responses. Funded by the European Research Council, the MMSCancer project proposes to combine strategies that mechanically modulate the tumour microenvironment. The synergistic effect of mechanotherapeutics and ultrasound sonopermeation is expected to improve drug delivery through impermeable tumours. Researchers will employ both computational modelling and experimentation to improve the methodology of these strategies.

Objective

Inefficient drug delivery to tumors can reduce dramatically treatment efficacy and thus, affect negatively the life of cancer patients. This is particularly evident in desmoplastic cancers where interactions among cancer cells, stromal cells and the fibrotic matrix cause tumor stiffening and accumulation of mechanical forces that compress tumor blood vessels. Indeed, in subsets of pancreatic cancers and sarcomas, 95% of intratumoral blood vessels may be compressed and up to 80% totally collapsed leading to reduced blood flow (hypo-perfusion) and drug delivery. Hypo-perfusion also leads to hypoxia that helps cancer cells evade the immune system and increase their invasive and metastatic potential. Use of mechanotherapeutics and ultrasound sonopermeation are two mechano-modulation strategies that separately have been employed to treat vascular abnormalities in tumors. Even though these strategies have reached the clinic, their promise has yet to be realized by cancer patients owning to limitations of the methods. My hypothesis is that these strategies can uniquely complement each other and have not only additive, but highly multiplicative synergistic effects on modulating the desmoplastic tumor microenvironment and improving the efficacy of the promising but still of limited use nano-immunotherapy. However, it is crucial that specific guidelines should be developed. To achieve this ground-breaking goal, I will employ a mixture of cutting-edge computational and experimental techniques. I will perform in vivo mice studies in pancreatic cancers and sarcomas to investigate under what conditions these mechano-modulation strategies can be optimally combined to improve treatment efficacy, prevent metastasis and increase survival. In parallel, I will develop new mathematical models to provide useful guidelines for optimizing the experimental protocol. MMSCancer will introduce novel therapeutic strategies for the treatment of drug resistant tumors leading to better therapies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-STG

See all projects funded under this call

Host institution

KYPRIAKO IDRYMA EREVNON GIA TI MYIKI DISTROFIA
Net EU contribution
€ 913 562,50
Address
6 IROON AVENUE
2371 AGIOS DOMETIOS
Cyprus
Region
Κύπρος Κύπρος Κύπρος
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 913 562,50

Beneficiaries (2)